A translational study reveals a role for interleukin-1–fibroblast–neutrophil signaling in drug-resistant inflammatory bowel disease, opening a potential path to targeted treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
D’Haens, G. R. et al. Gut 70, 1396–1405 (2021).
Feagan, B. G. et al. N. Engl. J. Med. 369, 699–710 (2013).
Sandborn, W. J. et al. N. Engl. J. Med. 369, 711–721 (2013).
Sandborn, W. J. et al. N. Engl. J. Med. 376, 1723–1736 (2017).
Feagan, B. G. et al. N. Engl. J. Med. 375, 1946–1960 (2016).
West, N. R. et al. Nat. Med. 23, 579–589 (2017).
Friedrich, M. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01520-5 (2021).
Buechler, M. B. et al. Nature 593, 575–579 (2021).
Kinchen, J. et al. Cell 175, 372–386 (2018).
Thomas, M. G. et al. BMJ Open 9, e023765 (2019).
Bersudsky, M. et al. Gut 63, 598–609 (2014).
Zhou, L. et al. Nature 568, 405–409 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Cader, M.Z., Kaser, A. Finding the right target for drug-resistant inflammatory bowel disease. Nat Med 27, 1870–1871 (2021). https://doi.org/10.1038/s41591-021-01551-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01551-y